Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. by Israel, Mason A et al.
UC San Diego
UC San Diego Previously Published Works
Title
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.
Permalink
https://escholarship.org/uc/item/8q31t167
Journal
Nature, 482(7384)
ISSN
0028-0836
Authors
Israel, Mason A
Yuan, Shauna H
Bardy, Cedric
et al.
Publication Date
2012-01-25
DOI
10.1038/nature10821
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Probing sporadic and familial Alzheimer’s disease using 
induced pluripotent stem cells
Mason A. Israel1,2, Shauna H. Yuan1,3, Cedric Bardy4, Sol M. Reyna1,2, Yangling Mu4, 
Cheryl Herrera1, Michael P. Hefferan5, Sebastiaan Van Gorp6, Kristopher L. Nazor7, 
Francesca S. Boscolo8, Christian T. Carson9, Louise C. Laurent8, Martin Marsala5,10, Fred 
H. Gage4, Anne M. Remes11, Edward H. Koo3, and Lawrence S. B. Goldstein1,3
1Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, University 
of California, San Diego, La Jolla, California 92093, USA 2Biomedical Sciences Graduate 
Program, University of California, San Diego, La Jolla, California 92093, USA 3Department of 
Neurosciences, University of California, San Diego, La Jolla, California, USA 4The Salk Institute 
for Biological Studies, La Jolla, California 92037, USA 5Department of Anesthesiology, University 
of California, San Diego, La Jolla, California 92093, USA 6Department of Anesthesiology, 
Maastricht University Medical Center, Maastricht 6202 AZ, Netherlands 7Department of Chemical 
Physiology, The Scripps Research Institute, La Jolla, California 92037, USA 8Department of 
Reproductive Medicine, University of California, San Diego, La Jolla, California 92093, USA 9BD 
Biosciences, La Jolla, California 92037, USA 10Institute of Neurobiology, Slovak Academy of 
Sciences, Kosice SK-04001, Slovakia 11Department of Clinical Medicine, Neurology and Clinical 
Research Center, University of Oulu, Oulu FIN-90015, Finland
Abstract
Our understanding of Alzheimer’s disease pathogenesis is currently limited by difficulties in 
obtaining live neurons from patients and the inability to model the sporadic form of the disease. It 
may be possible to overcome these challenges by reprogramming primary cells from patients into 
induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two 
patients with familial Alzheimer’s disease, both caused by a duplication of the amyloid-β 
precursor protein gene1 (APP; termed APPDp), two with sporadic Alzheimer’s disease (termed 
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sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from 
differentiated cultures were purified with fluorescence-activated cell sorting and characterized. 
Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA 
samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells 
exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified 
neurons from the two APPDp patients and patient sAD2 exhibited significantly higher levels of the 
pathological markers amyloid-β(1–40), phospho-tau(Thr 231) and active glycogen synthase 
kinase-3β (aGSK-3β). Neurons from APPDp and sAD2 patients also accumulated large RAB5-
positive early endosomes compared to controls. Treatment of purified neurons with β-secretase 
inhibitors, but not γ-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) 
and aGSK-3β levels. These results suggest a direct relationship between APP proteolytic 
processing, but not amyloid-β, in GSK-3β activation and tau phosphorylation in human neurons. 
Additionally, we observed that neurons with the genome of one sAD patient exhibited the 
phenotypes seen in familial Alzheimer’s disease samples. More generally, we demonstrate that 
iPSC technology can be used to observe phenotypes relevant to Alzheimer’s disease, even though 
it can take decades for overt disease to manifest in patients.
Alzheimer’s disease is a common neurodegenerative disorder, defined post mortem by the 
increased presence of amyloid plaques and neurofibrillary tangles in the brain2. Amyloid 
plaques are extracellular deposits consisting primarily of amyloid-β peptides, and 
neurofibrillary tangles are intraneuronal aggregations of hyperphosphorylated tau, a 
microtubule-associated protein involved in microtubule stabilization3. The causative 
relationship between amyloid plaque/amyloid-β and tau pathologies is unclear in humans. 
Although the vast majority of Alzheimer’s disease is apparently sporadic with significant 
non-Mendelian genetic contributions4, analyses of cellular and animal models of rare, 
dominantly inherited familial forms of Alzheimer’s disease have driven most ideas about 
disease mechanisms. These rare cases have mutations or a duplication of APP, which 
encodes the amyloid-β precursor protein, or mutations in the presenilin genes, which encode 
proteolytic enzymes that cleave APP into amyloid-β and other fragments. Mouse models 
that overexpress familial Alzheimer’s disease mutations develop extensive plaque deposition 
and amyloid-associated pathology, but neurofibrillary tangles and significant neuronal loss 
are conspicuously absent5,6. Fetal human cortical cultures have also been used to study the 
APP–tau relationship. For example, cortical cultures treated with 20 μM amyloid-β have 
elevated phosphorylated tau (p-tau)7. However, it is still unclear whether physiologically 
relevant levels of amyloid-β directly cause elevated p-tau and which kinases are directly 
involved in this aberrant phosphorylation. Additionally, experimental approaches using fetal 
human neurons are hindered by limited availability of samples and unknown genetic 
backgrounds. The recent developments in iPSCs and induced neurons have allowed 
investigation of phenotypes of neurological diseases in vitro8,9,10. However, not all diseases 
have been successfully modelled using iPSCs11, and it is unclear whether iPSCs can be used 
to study sporadic forms of disease.
Here we report the derivation and neuronal differentiation of iPSCs from patients with 
familial and sporadic Alzheimer’s disease, as well as from non-demented, age-matched 
controls. Using purified human neurons we probe three key questions concerning 
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Alzheimer’s disease: (1) can iPSC technology be used to observe phenotypes of patients 
with Alzheimer’s disease, even though it can take decades for overt disease to manifest; (2) 
is there a causative relationship between APP processing and tau phosphorylation; and (3) 
can neurons with the genome of a sAD patient exhibit phenotypes seen in familial 
Alzheimer’s disease samples? Supplementary Fig. 1 summarizes the experimental approach 
and findings.
We characterized APP metabolism in fibroblasts before reprogramming to iPSCs 
(Supplementary Fig. 2). APP expression and amyloid-β secretion were quantified in early-
passage primary fibroblasts from two non-demented control (NDC) individuals, two sAD 
patients and two APPDp patients (Table 1). The presence of the genomic duplication was 
confirmed in fibroblasts. Relative to NDC and sAD cells, APPDp fibroblasts expressed 
higher levels of APP mRNA and secreted 1.5- to twofold higher amounts of amyloid-β(1–
40) peptides into culture media compared to NDC cells. We did not detect significant 
increases in amyloid-β(1–42/1–40) or amyloid-β(1–38/1–40) in patient samples versus 
controls.
We generated iPSC lines by transducing fibroblasts with retro-viruses encoding OCT4, 
SOX2, KLF4, c-MYC and, in one-third of cultures, EGFP. Each of the six individuals was 
represented by three clonal iPSC lines. All 18 iPSC lines maintained embryonic stem (ES)-
cell-like morphology, expressed the pluripotency-associated proteins NANOG and 
TRA1-81, maintained euploid karyotypes, expressed endogenous locus-derived SOX2, 
repressed retroviral transgenes, and could differentiate into cells of ectodermal, mesodermal 
and endodermal lineages in vitro (Fig. 1a–d, Supplementary Figs 3a–e and 4). All lines 
tested (one per individual) formed teratomas when injected into nude rats (Supplementary 
Fig. 5). Supplementary Table 1 provides details of each iPSC line.
Variability in differentiation efficiency exists between pluripotent cell lines. To analyse 
variability in our iPSC lines, we used a fluorescence-activated cell sorting (FACS)-based 
method of neuronal differentiation and purification (summarized in Supplementary Fig. 6), 
based on work described previously12. Briefly, the 18 iPSC lines were first differentiated in 
to cultures containing neural rosettes (Supplementary Fig. 3f). From these cultures, neural 
progenitor cells (NPCs) were purified and the efficiency of NPC formation was assessed by 
CD184+CD15+CD44−CD271− immunoreactivity. These FACS-purified NPCs maintained 
expression of NPC-associated markers, such as SOX2 and nestin, over multiple passages 
(Fig. 1c, d). NPCs were differentiated for 3 weeks into heterogeneous cultures containing 
neurons (Supplementary Fig. 3g, h). APP copy number was faithfully maintained in 
differentiated cultures (Supplementary Fig. 3i). From these cultures, neurons were purified 
to near homogeneity, and the efficiency of neuron generation was assessed by 
CD24+CD184−CD44− immunoreactivity. No significant differences between any of the 
individuals in the efficiency of NPC or neuronal differentiation were detected (Fig. 1k, l).
Although we observed variability in differentiation among lines from each individual, the 
extent of inter-individual variation was less than observed intra-individual variability. These 
results suggest that any observed biochemical aberrations in neurons, if present in multiple 
lines derived from the same patient, are probably caused by features of that patient’s 
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genotype. Purified neurons were plated at a density of 2 × 105 cells per well of a 96-well 
plate and cultured for an additional 5 days. More than 90% of cells in these cultures were 
neurons, as judged by the presence of βIII-tubulin+, MAP2+ projections (Fig. 1e–h). 
Genome-wide mRNA expression profiles of five representative purified neuronal cultures 
were compared to the parental iPSC lines and samples from fetal brain, heart, liver and lung 
(Supplementary Fig. 7 and Supplementary Table 2). Unsupervised hierarchical clustering 
analysis revealed that purified neurons most closely resembled fetal brain samples, in part 
due to a global upregulation of neuronal genes. Interestingly, the largest difference between 
fetal brain samples and purified neurons was downregulation in purified neurons of the 
hippo signalling cascade (~6.1 fold), which regulates proliferation of cells such as NPCs and 
glia13,14.
We determined multiple electrophysiological properties of purified neurons to assess passive 
membrane properties and synaptic connectivity (Fig. 1i, j, Supplementary Table 3 and 
Supplementary Fig. 8). Notably, virtually all neurons tested generated voltage-dependent 
action potentials and currents (Fig. 1i), which were blocked by tetrodotoxin (Supplementary 
Fig. 8). Transient bath application of ionotropic receptor agonists (25 μM muscimol or 10 
μM AMPA) evoked transient currents, showing that purified neurons expressed functional 
GABA and AMPA receptors, respectively (Supplementary Table 3). To determine whether 
neurons were also able to form functional synaptic contacts, we analysed continuous whole-
cell voltage clamp recordings. We detected spontaneous inhibitory and/or excitatory 
synaptic currents in a subset of cells (~40%). Analysis of the kinetics of those events 
combined with reversible blockade using GABAA or AMPA receptor antagonists 
demonstrated that the neurons not only fire action potentials but also made functional 
synaptic contacts (Supplementary Table 3). The electrophysiological results were supported 
by analysis of expression of protein markers of glutamatergic and GABAergic neuronal 
subtypes (VGluT1 and GABA, respectively), which were detected by immunofluorescence, 
with approximately 15% of cells staining brightly for VGluT1 and 8% for GABA, and most 
remaining neurons staining dimly for one of the markers (Supplementary Fig. 9a). RNAs 
indicative of glutamatergic, GABAergic and cholinergic subtypes (that is, VGLUT1, GAD67 
and CHAT, respectively) were detected by quantitative polymerase chain reaction (qPCR). 
Importantly, no significant differences in neuronal subtypes were detected between patients 
and controls (Supplementary Fig. 9b–f).
Elevated or altered secretion of amyloid-β peptides by fibroblasts is a feature common to all 
familial Alzheimer’s disease mutations identified so far15,16. It is not known if iPSC-derived 
neurons from familial Alzheimer’s disease patients maintain the elevated amyloid-β 
production seen in the parental fibroblasts. In sAD fibroblasts and other peripheral cells, 
APP expression and amyloid-β secretion are not consistently altered17. To determine if 
iPSC-derived neurons from APPDp and sAD patients exhibit elevated amyloid-β secretion, 
amyloid-β levels in neuron-conditioned media were measured and normalized to total 
protein levels of cell lysates. Purified neurons from patients APPDp1 and APPDp2, each 
represented by three independently derived iPSC lines, secreted significantly higher levels 
of amyloid-β(1–40) compared to mean NDC levels (Fig. 2a). Neurons from patient sAD2 
also had significantly higher amyloid-β(1–40) levels compared to NDC neurons, even 
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though no difference was observed between the fibroblasts of sAD2 and NDC individuals. 
We found that amyloid-β(1–42) and amyloid-β(1–38) levels in these purified neuronal 
cultures were often below the detection range of our assay, owing to the relatively small 
number of neurons purified. By cell type, neurons exhibited a larger difference in amyloid-β 
levels between APPDp and NDC than fibroblasts, further suggesting that fibroblasts are not 
fully predictive of neuronal phenotypes (Fig. 2b).
Genetic evidence implicates altered or elevated APP processing and amyloid-β levels as the 
driving agents behind familial Alzheimer’s disease2 and, because of identical 
neuropathology, sporadic Alzheimer’s disease. However, tau, although not genetically 
linked to Alzheimer’s disease, forms neurofibrillary tangles, which correlate better with 
disease severity than plaque numbers18. The mechanism by which altered APP processing 
might cause elevated p-tau and neurofibrillary tangle pathology is unclear. Tau 
phosphorylation at Thr 231, one of several tau phosphoepitopes, regulates microtubule 
stability19 and correlates with both neurofibrillary tangle number and degree of cognitive 
decline20,21. To determine if tau phosphorylation at Thr 231 is elevated in APPDp and sAD 
neurons, we measured the amount of p-tau(Thr 231) relative to total tau levels in lysates 
from purified neurons from three iPSC lines from each of the NDC, sAD and APPDp 
patients. Neurons from both APPDp patients had significantly higher p-tau/total tau ratios 
than neurons from NDC lines (Fig. 2c). p-Tau/total tau in the two sAD patients mirrored the 
amyloid-β findings: no difference was observed between sAD1 and NDC neurons whereas 
sAD2 neurons had significantly increased p-tau/total tau.
Tau can be phosphorylated by multiple kinases. The kinase GSK-3β can phosphorylate tau 
at Thr 231 in vitro and co-localizes with neurofibrillary tangles and pre-tangle 
phosphorylated tau in sAD postmortem neurons22. GSK-3β is thought to be constitutively 
active but is inactivated when phosphorylated at Ser 9 (ref. 23). To determine if iPSC-
derived neurons with elevated p-tau have increased GSK-3β activity, the proportion of 
aGSK-3β in purified neurons was calculated by measuring the amount of GSK-3β lacking 
phosphorylation at Ser 9 relative to total GSK-3β levels. We observed that neurons from 
patients APPDp1, APPDp2 and sAD2 had significantly higher aGSK-3β than NDC neurons 
(Fig. 2d). The amyloid-β, GSK-3β and tau findings of sAD2 were verified by analysing an 
additional two iPSC lines (sAD2.4 and sAD2.5; characterization in Supplementary Fig. 10), 
and we observed that levels remained consistently elevated (Fig. 2e). Results are detailed per 
patient in Supplementary Table 4a, per cell line in Supplementary Fig. 11, and per cell 
culture in Supplementary Table 5.
Although amyloid-β, p-tau and GSK-3β clearly have roles in Alzheimer’s disease 
pathogenesis, their relationship is unclear. We observed that iPSC-derived neurons exhibited 
strong or very strong correlations between amyloid-β(1–40), p-tau/total tau and aGSK-3β 
levels (Fig. 2f and Supplementary Table 4b). We reasoned that if APP proteolytic products, 
such as amyloid-β or carboxy-terminal fragments (CTFs), have a causative role in p-tau and 
aGSK-3β elevation, then inhibiting γ- or β-secretase activity could reduce p-tau and 
aGSK-3β. We treated purified neurons from NDC1, NDC2, sAD2 and APPDp2 (2–3 iPSC 
lines each) with γ-secretase inhibitors (CPD-E and DAPT) or β-secretase inhibitors (βSi-II 
and OM99-2) for 24 h and measured amyloid-β, GSK-3β and p-tau/total tau compared to 
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vehicle-treated samples. All inhibitors reduced amyloid-β(1–40) by similar levels (32–45% 
in patient samples) (Fig. 2g). Intriguingly, for both sAD2 and APPDp2 neurons, we observed 
that β-secretase inhibitors significantly reduced aGSK-3β and p-tau/total tau (Fig. 2g, and 
shown per iPSC line in Supplementary Fig. 12). Neither γ-secretase inhibitor significantly 
differed from control-treated samples for aGSK-3β levels and p-tau/total tau.
We extended phenotypic characterization of sAD2 and APPDp by analysing endosomal and 
synaptic markers in FACS-purified neurons co-cultured with astrocytes for 12 days. 
Accumulation of large RAB5+ early endosomes in neurons has been observed in autopsies 
from sporadic Alzheimer’s disease and some forms of familial Alzheimer’s disease24,25. As 
β-secretase is localized to endosomes and has an acidic pH optimum, it has been proposed 
that early endosomes potentially mediate the effects of APP processing on downstream 
pathologies such as increased p-tau, neurofibrillary tangles, synaptic loss and apoptosis26; 
however, these hypotheses have been difficult to test directly without live, patient-specific 
neurons. To determine if early endosome phenotypes are present in iPSC-derived neurons 
from Alzheimer’s disease patients, purified neurons from NDC1, NDC2, sAD2 and APPDp2 
(two iPSC lines each) co-cultured with astrocytes were harvested and large and very large 
Rab5+ early endosomes (1–2.1 μm3 and 2.1–7 μm3) in neuronal soma were counted. 
Whereas control neurons generally had few Rab5+ structures >1 μm3, neurons from both 
sAD2 and APPDp2 frequently had Rab5+ early endosomes highly similar in volume, 
morphology and localization to what has been observed in autopsy samples (Fig. 3a–c). 
When compared, the neurons from both sAD2 and APPDp2 had significantly increased 
numbers of both large and very large early endosomes relative to controls (Fig. 3d). We 
sought to determine if neuronal cultures from sAD2 and APPDp2 also contained reduced 
levels of the presynaptic marker synapsin I. In Alzheimer’s disease autopsies, synaptic loss 
is one of the strongest pathological correlates with dementia severity, and in regions of the 
brain affected by Alzheimer’s disease, the presynaptic marker synapsin I is decreased in 
patients versus controls27,28. To analyse synapsin I levels in iPSC-derived neurons co-
cultured with astrocytes, we quantified synapsin I+ puncta on MAP2+ dendrites (Fig. 3e). 
We found no significant difference between NDCs and either sAD2 or APPDp2 in the 
number of puncta per μm dendrite (Fig. 3f). Extended culture periods may be required to 
study Alzheimer’s disease-associated loss of synaptic proteins.
The results of this study provide strong evidence that iPSC technology can be used in 
concert with post-mortem samples and animal models to study early pathogenesis and drug 
response in sporadic and familial Alzheimer’s disease. In purified, electrophysiologically 
active neurons from one sporadic Alzheimer’s disease and two APPDp patients, each 
represented by at least three clonally derived iPSC lines, we observed significantly increased 
levels of three major biochemical markers of Alzheimer’s disease: amyloid-β(1–40), 
aGSK-3β and p-tau/total tau. Increased sAD2 amyloid-β levels were not observed in the 
parental fibroblasts, suggesting a cell-type-specific phenotype. Among the individuals in this 
study, not only did strong correlations exist between amyloid-β(1–40), p-tau/total tau and 
aGSK-3β, but both p-tau/total tau and aGSK-3β levels were also partially rescued in neurons 
from sAD2 and APPDp following treatment with β-secretase inhibitors, suggesting that the 
APP processing pathway has a causative role in tau Thr 231 phosphorylation in human 
neurons. Because γ-secretase inhibition did not cause a significant effect, products of APP 
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processing other than amyloid-β may have a role in induction of GSK-3β activity and p-tau. 
One potential culprit is the β-CTF, the levels of which correlate with axonopathies in mouse 
models harbouring APP duplications29 and mediate early endosome accumulation in human 
Down’s syndrome fibroblasts30. The observation that neurons from patients sAD2 and 
APPDp2 have early endosome phenotypes raises the question of how aberrant early 
endosomes relate to other phenotypes of Alzheimer’s disease, such as axonopathies, 
synaptic loss and cell death, in human neurons. Neurons and synapses rely heavily on 
endocytic pathways, and thus iPSC technology can now be used to study the role of this 
dynamic process in live patient-specific neurons. One point of caution is that it is possible 
that the cultures of purified neurons that we generated and studied may not have been fully 
mature, as they lacked repetitive action potentials and had limited spontaneous activity. 
Although some types of mature neurons also have these properties, it is conceivable that the 
phenotypes we observed might be modified by duration of in vitro culture. In this context, 
while there is debate about when Alzheimer’s disease phenotypes initiate, evidence exists 
that Alzheimer’s disease-like pathology can occur in Down’s syndrome fetuses as early as 
28 weeks of gestation24.
Our finding that the genome of patient sAD2, but not patient sAD1, generates significant 
Alzheimer’s disease phenotypes in purified neurons has important implications. First, this 
finding suggests that an unknown frequency of sporadic Alzheimer’s disease patients will 
have genomes that generate strong neuronal phenotypes. The frequency of such genomes in 
the sporadic Alzheimer’s disease population cannot be determined from the small sample 
size we report and will require a larger sample size to ask how frequent such genomes are in 
the clinical population diagnosed with sporadic Alzheimer’s disease. Second, the genome of 
sAD2 clearly harbours one or more variants that generate Alzheimer’s disease phenotypes, 
which can thus be elucidated by future molecular genetic studies. Third, we speculate that 
sporadic Alzheimer’s disease might be sub-divided depending on whether neurons 
themselves are altered, as in the case of sAD2, as opposed to other cell types such as 
astrocytes, which could be altered in other cases, for example, sAD1. Thus, future iPSC 
studies examining larger numbers of patients and controls have the potential to provide great 
insight into the mechanisms behind the observed heterogeneity in sporadic Alzheimer’s 
disease pathogenesis, the role of different cell types, patient-specific drug responses, and 
prospective diagnostics.
METHODS SUMMARY
iPSC generation and differentiation
Primary fibroblast cultures were established from dermal punch biopsies taken from 
individuals following informed consent and Institutional Review Board approval. To 
generate iPSCs, fibroblasts were transduced with MMLV vectors containing the 
complementary DNAs for OCT4, SOX2, KLF4, c-MYC and ± EGFP. IPSC-derived NPCs 
were differentiated for 3 weeks, neurons were purified by FACS, and amyloid-β, p-tau/total 
tau and aGSK-3β were measured on purified control and mutant neurons from multiple lines 
cultured in parallel for an additional 5 days by multi-spot electrochemiluminescence assays 
(Meso Scale Diagnostics). Early endosomes were analysed by confocal microscopy on 
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purified neurons co-cultured with human astrocytes (Lonza) for 12 days. To ensure 
reproducible and consistent data, we found that it is important to differentiate and evaluate 
neurons from full sets of mutant and control iPSC lines together.
Statistics
P < 0.05 was considered statistically significant. Individuals were statistically compared to 
the total NDC pool by Tukey’s test. Drug responses were compared to controls by Dunnett’s 
method. N values signify the total number of separate cultures analysed, with each iPSC line 
contributing equally to the total.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Generation of iPSC lines and purified neurons from APPDp, sAD and NDC fibroblasts
a, b, iPSC lines express NANOG and TRA1-81. c, d, iPSC-derived, FACS-purified NPCs 
express SOX2 and nestin. e–h, iPSC-derived, FACS-purified neurons express MAP2 and 
βIII-tubulin. Scale bars in a–h, 50 μm. i, Representative action potentials in response to 
somatic current injections. Data from iPSC line APPDp2.2. j, Spontaneous synaptic activity 
was detected (voltage clamp recording at the reversal potential of sodium (0 mV)) and 
reversibly blocked by GABAA receptor antagonist SR95531 (10 μM). Each panel represents 
~4 min continuous recordings separated in 25 sweeps (grey traces) and superimposed for 
clarity. Black traces represent a single sweep. Data from iPSC line NDC2.1. k, l, No 
significant difference was seen between NDCs and any patient’s cultures in the ability of 
iPSCs to generate NPCs at day 11 (P = 0.08, n = 9), or the ability of NPCs to form neurons 
at 3 weeks (P = 0.82, n = 9). Error bars indicate s.e.m.
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Figure 2. Increased amyloid-β, p-tau and aGSK-3β in sAD2 and APPDp neuronal cultures
a, Purified neurons from sAD2, APPDp1 and APPDp2 secrete increased amyloid-β(1–40) 
(Aβ(1–40)) compared to NDC samples (P = 0.0012, 0.0014 and < 0.0001, respectively). b, 
Amyloid-β differences between patients and controls are larger in neurons versus fibroblasts. 
Data sets are relative to NDC mean. c, d, Neurons from sAD2, APPDp1 and APPDp2 have 
increased aGSK-3β (percentage non-phospho-Ser 9) and p-tau/total tau (p-tau/t-tau) 
compared to NDC samples (aGSK-3β, P < 0.0001, 0.0005 and 0.0001; p-tau/total tau, P < 
0.0001, 0.0001 and 0.0002). In a–d, n values on graphs indicate the number of biological 
replicates per patient, contributed equally by three iPSC lines. e, sAD2 findings verified in 
two additional iPSC lines (sAD2.4 and sAD2.5). sAD2(1-3) indicates findings from initial 
sAD2 iPSC lines. For amyloid-β, aGSK-3β and p-tau/total tau, sAD2 remained significantly 
higher than controls (P < 0.0001). No significant difference was found between original and 
secondary sAD2 lines (P = 0.14, 0.44, 0.63). f, Strong positive correlations between 
amyloid-β(1–40), aGSK-3β and p-tau/total tau in purified neurons. Pearson R = 0.94, 0.91 
and 0.83, respectively. g, Twenty-four hour treatment with β- and γ-secretase inhibitors 
reduced secreted amyloid-β(1–40) compared to control treatment. β-Secretase inhibitors 
partially rescued aGSK-3β and p-tau/total tau in sAD2 and APPDp2 neurons (P < 0.01 for 
aGSK-3β, P < 0.03 for p-tau). γ-Secretase inhibition did not significantly affect aGSK-3β 
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and p-tau/total tau. In g, number of treatment sets is indicated on the graph (n), NDCs are 
represented by two iPSC lines each and sAD2 and APPDp2 are represented by three. Error 
bars indicate s.e.m.
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Figure 3. Analysis of early endosome and synapsin levels in purified neurons co-cultured with 
astrocytes
a–c, Extended focus images of Rab5-stained neuronal soma from NDC1, sAD2 and 
APPDp2. Arrowhead in b marks a 1–2.1 μm3 early endosome, and the arrow marks a 2.1–7 
μm3 early endosome. Scale bars, 10 μm. d, Neurons from sAD2 and APPDp2 have 
significantly increased numbers of large and very large early endosomes compared to NDC 
neurons (P < 0.0001, n = 40 neurons from two iPSC lines per individual). e, Representative 
image of synapsin I (green) on a MAP2+ dendrite (red). Arrowhead marks a synapsin I+ 
punctum. Scale bar, 3 μm. f, No significant difference between patients and controls in the 
number of synapsin+ structures per μm dendrite (P = 1.00, n = 40 dendrites from two iPSC 
lines per individual). Neurons were scored blinded to genotype. Error bars indicate s.e.m.
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